KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Accounts Payables (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Accounts Payables for 16 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 718.08% to $11.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.1 million through Dec 2025, up 718.08% year-over-year, with the annual reading at $11.1 million for FY2025, 718.08% up from the prior year.
  • Accounts Payables hit $11.1 million in Q4 2025 for Inovio Pharmaceuticals, up from $379721.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $105.0 million in Q2 2022 to a low of $369000.0 in Q2 2025.
  • Historically, Accounts Payables has averaged $21.6 million across 5 years, with a median of $13.8 million in 2024.
  • Biggest YoY gain for Accounts Payables was 1526.28% in 2023; the steepest drop was 99.04% in 2023.
  • Year by year, Accounts Payables stood at $47.6 million in 2021, then plummeted by 97.44% to $1.2 million in 2022, then surged by 1526.28% to $19.8 million in 2023, then tumbled by 93.19% to $1.4 million in 2024, then skyrocketed by 718.08% to $11.1 million in 2025.
  • Business Quant data shows Accounts Payables for INO at $11.1 million in Q4 2025, $379721.0 in Q3 2025, and $369000.0 in Q2 2025.